Evidence map›Paper›PMID 25466890›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2015

Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.

Angelica Ortiz, Yu-Chen Lee, Guoyu Yu, Hsuan-Chen Liu, Song-Chang Lin, Melmet Asim Bilen, Hyojin Cho, Li-Yuan Yu-Lee, Sue-Hwa Lin

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Role of angiomotin family members in human diseases (Review).Experimental and therapeutic medicine · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. How many cadherins do human endothelial cells express?Cellular and molecular life sciences : CMLS · 2019
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Angiomotin Family Members: Oncogenes or Tumor Suppressors?International journal of biological sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angelica OrtizDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Yu-Chen LeeDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Guoyu YuDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Hsuan-Chen LiuDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Song-Chang LinDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Melmet Asim BilenDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Hyojin ChoDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Li-Yuan Yu-LeeDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Sue-Hwa LinDepartments of *Translational Molecular Pathology and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA; and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA slin@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Endothelial-to-osteoblast transition in prostate cancer bone metastasisR01CA174798 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, SUE-HWA · 2013 to 2023
$3.0M
NCI NIH HHS CA16672NCI NIH HHS CA174798NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS P50CA140388NCI NIH HHS R01 CA174798
6 · The paper itself

Abstract

Loss of E-cadherin and up-regulation of mesenchymal cadherins, a hallmark of the epithelial-mesenchymal transition, contributes to migration and dissemination of cancer cells. Expression of human cadherin-11 (Cad11), also known as osteoblast cadherin, in prostate cancer increases the migration of prostate cancer cells. How Cad11 mediates cell migration is unknown. Using the human Cad11 cytoplasmic domain in pulldown assays, we identified human angiomotin (Amot), known to be involved in cell polarity, migration, and Hippo pathway, as a component of the Cad11 protein complex. Deletion analysis showed that the last C-terminal 10 amino acids in Cad11 cytoplasmic domain are required for Amot binding. Further, Cad11 preferentially interacts with Amot-p80 than Amot-p130 isoform and binds directly to the middle domain of Amot-p80. Cad11-Amot interaction affects Cad11-mediated cell migration, but not homophilic adhesion, as deletion of Amot binding motif of Cad11 (Cad11-ΔAmot) did not abolish Cad11-mediated cell-cell adhesion of mouse L cells, but significantly reduced Cad11-mediated cell migration of human C4-2B4 and PC3-mm2 prostate cancer cells and human HEK293T cells. Together, our studies identified Amot-p80 as a novel component of the Cad11 complex and demonstrated that Amot-p80 is critical for Cad11-mediated cell migration.

Indexed as

Cell MovementAmino Acid SequenceAngiomotinsAnimalsbeta CateninBlotting, WesternCadherinsCell AdhesionCell ProliferationCells, CulturedFluorescent Antibody TechniqueHEK293 CellsHumansImmunoenzyme TechniquesImmunoprecipitationIntercellular Signaling Peptides and ProteinsAMOT protein, humanAngiomotinsbeta CateninCadherinsCTNNB1 protein, humanIntercellular Signaling Peptides and ProteinsMembrane ProteinsMicrofilament Proteinsosteoblast cadherinp120 GTPase Activating ProteinProtein IsoformsRNA, MessengeradhesionE-cadherinOB-cadherinprostate cancer

Identifiers

PMID25466890
PMCPMC4422367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.